Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 4Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 2Endocrine 1

Conditions

Thyroid Neoplasms 2Thyroid Cancer, Papillary 1Sexual Dysfunction, Physiological 1Neoplasms 1Eunuchism 1Erectile Dysfunction 1Carcinoma, Non-Small-Cell Lung 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3Iodine-131 3Iodine-124 3Biopsy 3selpercatinib 2lenvatinib 2Watchful Waiting 2Thyrotropin Alfa 2Therapeutics 2Nivolumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Cetuximab 2Biopsy, Fine-Needle 2trastuzumab deruxtecan 1trametinib 1sintilimab 1sacituzumab govitecan 1repotrectinib 1pralsetinib 1pembrolizumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1defactinib 1dabrafenib 1cemiplimab 1brodalumab 1binimetinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Thyroid Neoplasms × selpercatinib × Clear all
NCT07419932 2026-02-19

NeoLATC

Fujian Medical University

Recruiting
120 enrolled
Head & Neck

Thyroid Neoplasms

NCT05668962 2024-12-12

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Massachusetts General Hospital

Phase 2 Recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡